Cart
sales@molnova.com
DMH-25
CAS No. 1685280-21-0
DMH-25( —— )
Catalog No. M22216 CAS No. 1685280-21-0
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 212 | In Stock |
|
| 5MG | 170 | In Stock |
|
| 10MG | 258 | In Stock |
|
| 25MG | 426 | In Stock |
|
| 50MG | 586 | In Stock |
|
| 100MG | 792 | In Stock |
|
| 200MG | 1051 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDMH-25
-
NoteResearch use only, not for human use.
-
Brief DescriptionDMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
-
DescriptionDMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptormTOR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1685280-21-0
-
Formula Weight489.94
-
Molecular FormulaC15H8Br3NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=[N+](C(C(C1=CC=C(Br)C=C1)O2)=CC3=C2C(Br)=CC(Br)=C3)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.amélie, fouqué, Delalande O , Jean M , et al. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells[J]. Journal of Medicinal Chemistry, 2015:6559-73.
molnova catalog
related products
-
Y16
Y16 is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.
-
ICSN3250
ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.
-
Tacrolimus
Tacrolimus is a macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity.
